RRP12: Potential Drug Target and Biomarker for Various Diseases

Target Name: RRP12

NCBI ID: G23223

RRP12

RRP12: Potential Drug Target and Biomarker for Various Diseases

Ribosomal RNA (rRNA) processing 12 (RRP12) is a protein that is expressed in most eukaryotic cells and is involved in the processing of rRNA into functional RNA molecules. This protein has been identified as a potential drug target and a biomarker for various diseases, including cancer, neurodegenerative diseases, and chronic obstructive pulmonary disease (COPD).

RRP12 is a key enzyme in the ribosome, which is the protein machine that synthesizes proteins in the cell. The ribosome is composed of several subunits, including a protein called rRNA, which is the primary template for protein synthesis. RRP12 is a 21-kDa protein that is involved in the processing of rRNA into functional RNA molecules.

RRP12 is a critical enzyme for the production of functional rRNA molecules, which are essential for protein synthesis in the cell. In addition to its role in protein synthesis, RRP12 is also involved in the regulation of gene expression and has been shown to play a role in the development and progression of various diseases.

RRP12 has been identified as a potential drug target due to its involvement in the production of cancer-associated proteins. Many studies have shown that cancer cells produce elevated levels of RRP12 and that inhibiting RRP12 function can lead to the inhibition of cancer cell growth and the development of cancer-associated proteins. In addition, RRP12 has also been shown to be involved in the production of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, which are characterized by the progressive loss of brain cells. The inhibition of RRP12 function has been shown to be effective in the treatment of these diseases.

RRP12 has also been identified as a potential biomarker for COPD, a progressive lung disease that is characterized by chronic coughing, shortness of breath, and decreased lung function. Many studies have shown that the expression of RRP12 is increased in the lungs of individuals with COPD and that inhibiting RRP12 function has been shown to be effective in the treatment of COPD. In addition, RRP12 has also been shown to be involved in the regulation of lung function and has been implicated in the development of COPD.

In conclusion, RRP12 is a protein that is involved in the processing of rRNA into functional RNA molecules and has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and COPD. The inhibition of RRP12 function has been shown to be effective in the treatment of these diseases and may be a valuable tool in the development of new therapies. Further research is needed to fully understand the role of RRP12 in the development and progression of these diseases and to determine its potential as a drug target and biomarker.

Protein Name: Ribosomal RNA Processing 12 Homolog

The "RRP12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RRP12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets